Beam Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 436
- Market Cap
- $2.1B
- Introduction
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Stephen Majors of the Alliance for Regenerative Medicine Previews Key Learnings for Over 2,000 Attendees at the Upcoming Phoenix Conference on Industry Challenges
Stephen Majors of the Alliance for Regenerative Medicine previews key learnings for over 2,000 attendees at the upcoming Phoenix conference on industry challenges.
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of ...
Beam Therapeutics announced successful long-term engraftment of base-edited hematopoietic stem cells and robust HbF induction using CD117 mAb conditioning in NHPs, with well-tolerated dosing and no need for supportive care, aiming to advance ESCAPE platform for SCD and beta-thalassemia.
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM
A form includes dropdowns for selecting a state, zip code, and country, with California pre-selected as the default state and the United States as the default country.
Sanofi advances a drug for a rare, platelet-destroying disease
Sanofi's rilzabrutinib shows promise in treating immune thrombocytopenia, while Novo Nordisk's etavopivat reduces sickle cell pain crises. Beam Therapeutics' CRISPR therapy for sickle cell yields consistent results, though fertility preservation remains a concern.
Sickle Cell Breakthrough: Base Editing Success
Branden Baptiste, 20, underwent base editing gene therapy for sickle cell disease at Boston Children's Hospital, becoming the first person to receive this treatment. The therapy, aimed at boosting fetal hemoglobin production, has significantly improved his condition, allowing him to resume normal activities and plan for a career in civil engineering.
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of ...
All seven patients treated with BEAM-101 achieved HbF induction >60%, HbS reduction <40%, and anemia resolution post-treatment. Safety profile consistent with busulfan conditioning and autologous HSCT. Rapid neutrophil and platelet engraftment observed. Hemolysis markers normalized or improved in all patients. Beam to host investor event on Dec. 8, 2024.
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial
All seven patients treated with BEAM-101 achieved HbF induction >60%, HbS reduction <40%, and anemia resolution. Safety profile consistent with busulfan conditioning and autologous HSCT. Rapid neutrophil and platelet engraftment observed. Hemolysis markers normalized or improved. No VOCs reported post-engraftment.
Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101
Beam Therapeutics' BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease showed all seven patients achieved HbF >60%, HbS <40%, resolved anemia, and normalized hemolysis markers. Rapid neutrophil and platelet engraftment occurred, with one patient death from busulfan-related respiratory failure. No vaso-occlusive crises were reported post-engraftment.
Beam Therapeutics Inc. Appoints Sravan K. Emany As Chief Financial Officer
Switch the Market flag for targeted data from your country of choice. Right-click on the chart to open the Interactive Chart menu. Use up/down arrows to move through symbols.
© Copyright 2025. All Rights Reserved by MedPath